MedTrace Logo

VISUPRIME® Eye Drops

NCT05677685 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-07-19

No results posted yet for this study

Summary

The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.

Conditions

  • Macular Degeneration, Age Related
  • Myopic Choroidal Neovascularisation
  • Proliferative Diabetic Retinopathy
  • Diabetic Macular Edema
  • Macular Edema of Right Retina (Diagnosis)

Interventions

DEVICE

VISUPRIME

twice daily

DEVICE

Placebo

twice daily

Sponsors & Collaborators

  • CROlife

    collaborator UNKNOWN

  • VISUfarma SpA

    lead INDUSTRY

Principal Investigators

  • Anna Rita Bigioni, PhD · CROlife

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-22
Primary Completion
2024-01-23
Completion
2024-01-23

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677685 on ClinicalTrials.gov